Helix Acquisition Corp III is a SPAC — a blank-check shell company with no operations — formed to raise capital through an IPO and use it to acquire a private company, taking it public. Helix III raised $172.25M in its January 2026 IPO at $10.00 per share, with those proceeds held in a trust account earning interest until an acquisition closes. The company intends to focus on healthcare and healthcare-related businesses, though it is not legally restricted to that sector. The sponsor, Helix Holdings III LLC, is controlled by Bihua Chen, who also serves as Chairperson and CEO, and is backed by two Cormorant healthcare-focused investment funds managed by Chen. The sponsor received roughly 4.25M Class B founder shares for a nominal $25,000 investment; if a deal closes, those shares convert to approximately 20% of post-combination equity — the standard SPAC "promote" structure. Public shareholders retain the right to redeem their shares at approximately $10.00 plus accrued trust interest if they disapprove of a proposed deal, capping their downside. Helix III has a 24-month window from its January 2026 IPO to complete a deal; if no deal closes, the trust is liquidated and public shareholders are returned their $10.00. The sponsor loses its entire investment in a liquidation scenario, concentrating the incentive to close a transaction.